MA42439B1 - Agents, utilisations et procédés pour le traitement d'une synucléinopathie - Google Patents
Agents, utilisations et procédés pour le traitement d'une synucléinopathieInfo
- Publication number
- MA42439B1 MA42439B1 MA42439A MA42439A MA42439B1 MA 42439 B1 MA42439 B1 MA 42439B1 MA 42439 A MA42439 A MA 42439A MA 42439 A MA42439 A MA 42439A MA 42439 B1 MA42439 B1 MA 42439B1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- parkinson
- synucleinopathy
- agents
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1512203.9A GB201512203D0 (en) | 2015-07-13 | 2015-07-13 | Agents,uses and methods |
| PCT/EP2016/066476 WO2017009312A1 (en) | 2015-07-13 | 2016-07-12 | Agents, uses and methods for the treatment of synucleinopathy |
| EP16738736.4A EP3322722B1 (en) | 2015-07-13 | 2016-07-12 | Agents, uses and methods for the treatment of synucleinopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42439A MA42439A (fr) | 2018-05-23 |
| MA42439B1 true MA42439B1 (fr) | 2025-05-30 |
Family
ID=54013851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42439A MA42439B1 (fr) | 2015-07-13 | 2016-07-12 | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
Country Status (40)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| RU2019114679A (ru) * | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| WO2018183192A1 (en) | 2017-03-27 | 2018-10-04 | Chase Therapeutics Corporation | Compositions and methods for treating synucleinopathies |
| AU2018258117A1 (en) | 2017-04-24 | 2019-12-12 | Chase Therapeutics Corporation | Compositions and method for treating depression |
| IL270361B2 (en) | 2017-05-01 | 2025-04-01 | Univ Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3672635A4 (en) | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF |
| BR112020009707A2 (pt) * | 2017-11-17 | 2020-10-13 | Abl Bio Inc. | anticorpos para a-sinucleína e usos dos mesmos |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| BR112020014542A2 (pt) * | 2018-01-26 | 2020-12-08 | Quantum-Si Incorporated | Aprendizado de máquina habilitado por aplicação de pulso e de base para dispositivos de sequenciamento |
| EP3752840A4 (en) * | 2018-02-12 | 2022-08-10 | The Scripps Research Institute | PROCEDURES RELATED TO PARKINSON'S DISEASE AND SYNUCLEINOPATHIES |
| EP3833435B1 (en) * | 2018-08-09 | 2025-09-24 | F. Hoffmann-La Roche AG | Determination of parkinson's disease |
| MX2021005048A (es) | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| CA3133909A1 (en) * | 2019-04-18 | 2020-10-22 | Elpida TSIKA | Novel molecules for therapy and diagnosis |
| US20220226357A1 (en) * | 2019-04-29 | 2022-07-21 | Thomas Jefferson University | Methods for treating neurodegenerative disorders |
| MX2022006676A (es) * | 2019-12-04 | 2022-07-05 | Ac Immune Sa | Nuevas moleculas para terapia y diagnostico. |
| KR102466943B1 (ko) * | 2020-04-02 | 2022-11-14 | 한국과학기술연구원 | 갭을 갖는 바이오 센서를 이용한 파킨슨병 모니터링 방법 및 시스템 |
| CN111537738A (zh) * | 2020-05-18 | 2020-08-14 | 南通大学附属医院 | 用于超早期帕金森病检测的试剂盒 |
| KR20240055785A (ko) * | 2021-09-01 | 2024-04-29 | 백시니티, 인크. | 시누클레인병증의 방지 및 치료 방법 |
| IL311344A (en) | 2021-09-16 | 2024-05-01 | H Lundbeck As | Preparations and methods for the treatment of synoclinopathies |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| WO2024177999A2 (en) * | 2023-02-21 | 2024-08-29 | The Regents Of The University Of Michigan | Human aggregated alpha-synuclein binding molecules |
| CN116077524A (zh) * | 2023-02-27 | 2023-05-09 | 广西馨海药业科技有限公司 | 氯化铷在制备治疗帕金森综合征的药物中的用途 |
| AU2024360083A1 (en) * | 2023-10-12 | 2026-05-21 | Universite Laval | Anti-alpha-synuclein antibodies and uses thereof |
| WO2025186235A1 (en) | 2024-03-05 | 2025-09-12 | H. Lundbeck A/S | Compositions and methods for treating multiple system atrophy (msa) |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1512203A (en) | 1974-05-08 | 1978-05-24 | Aspin F | Rolls for use in profiling film |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988004777A1 (en) | 1986-12-15 | 1988-06-30 | Ultra Diagnostics Corporation | Monomeric phthalocyanine reagents |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2065299C (en) | 1989-08-09 | 2001-07-24 | Buck A. Rhodes | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
| AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| CN1399645A (zh) | 1999-07-29 | 2003-02-26 | 米德列斯公司 | Her2/neu的人单克隆抗体 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| CN1440420A (zh) | 2000-07-07 | 2003-09-03 | 万能药制药公司 | 预防神经组织损伤和治疗α－共核蛋白疾病的方法 |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| US8829198B2 (en) | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DK2361928T3 (en) | 2003-05-19 | 2017-07-03 | Prothena Biosciences Ltd | Truncated fragments of alpha synuclein in Lewy body disease |
| WO2005047860A2 (en) * | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2006031250A (ja) | 2004-07-14 | 2006-02-02 | Fuji Xerox Co Ltd | 通信装置およびその制御方法 |
| CN101052417A (zh) * | 2004-08-09 | 2007-10-10 | 艾兰制药公司 | 突触核蛋白病以及淀粉样变性病的预防和治疗 |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US20060205024A1 (en) | 2005-03-08 | 2006-09-14 | Sun Health Research Institute | Method to diagnose and evaluate progression of Alzheimer's disease |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| LT3067066T (lt) | 2007-02-23 | 2019-06-25 | Prothena Biosciences Limited | Sinukleopatinių ir amiloidogeninių ligų prevencija ir gydymas |
| PL2583978T3 (pl) | 2007-02-23 | 2016-07-29 | Prothena Biosciences Ltd Co | Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych |
| CN104383556B (zh) * | 2007-05-16 | 2018-06-05 | 布里格姆妇女医院 | 突触核蛋白病的治疗 |
| JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル．エル．シー． | Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例 |
| ES2709048T3 (es) | 2008-04-29 | 2019-04-15 | Bioarctic Ab | Anticuerpos y vacunas para su uso en métodos terapéuticos y diagnósticos para trastornos relacionados con alfasinucleína |
| HRP20150831T1 (hr) * | 2008-12-19 | 2015-10-09 | Biogen International Neuroscience Gmbh | Humana anti-alfa- sinuklein auto-protutijela |
| CA2758187C (en) | 2009-04-09 | 2017-03-07 | Robert Boyd | Methods for preventing and/or treating degenerative disorders of the central nervous system |
| CN110655573B (zh) | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| GB201008682D0 (en) | 2010-05-25 | 2010-07-07 | Vib Vzw | Epitope tag for affinity based applications |
| LT2627672T (lt) | 2010-10-11 | 2018-12-10 | Biogen International Neuroscience Gmbh | Žmogaus antikūnai prieš tau baltymą |
| PL2723379T3 (pl) * | 2011-06-23 | 2019-05-31 | Biogen Int Neuroscience Gmbh | Cząsteczki wiążące przeciwko alfa-synukleinie |
| JP2013059866A (ja) | 2011-09-12 | 2013-04-04 | Seiko Epson Corp | 液体噴射装置、液体噴射装置の制御方法および液体噴射装置の制御プログラム |
| EP2771031B1 (en) * | 2011-10-28 | 2018-04-18 | Prothena Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| EP2870176A4 (en) | 2012-07-03 | 2016-09-28 | Univ Washington | ANTIBODIES DIRECTED AGAINST TAU |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| CN104869993B (zh) | 2012-10-25 | 2019-01-15 | 通用医疗公司 | 治疗阿尔茨海默病及相关疾病的组合疗法 |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| LT3071597T (lt) * | 2013-11-21 | 2020-10-12 | F. Hoffmann-La Roche Ag | Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| WO2016179569A1 (en) | 2015-05-07 | 2016-11-10 | Axovant Sciences Ltd. | Compositions and methods of treating a neurodegenerative disease |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| TW202309093A (zh) | 2016-06-02 | 2023-03-01 | 英商梅迪繆思有限公司 | 針對α-突觸核蛋白之抗體及其用途 |
| RU2019114679A (ru) | 2016-11-15 | 2020-12-17 | Х. Лундбекк А/С | Средства, пути применения и способы лечения синуклеопатии |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
-
2015
- 2015-07-13 GB GBGB1512203.9A patent/GB201512203D0/en not_active Ceased
-
2016
- 2016-07-11 JO JOP/2016/0140A patent/JO3692B1/ar active
- 2016-07-12 US US15/207,859 patent/US10800836B2/en active Active
- 2016-07-12 PE PE2018000066A patent/PE20181049A1/es unknown
- 2016-07-12 FI FIEP16738736.4T patent/FI3322722T3/fi active
- 2016-07-12 CN CN202511963296.1A patent/CN121736097A/zh active Pending
- 2016-07-12 KR KR1020177037733A patent/KR102793383B1/ko active Active
- 2016-07-12 WO PCT/EP2016/066476 patent/WO2017009312A1/en not_active Ceased
- 2016-07-12 AR ARP160102110A patent/AR105336A1/es unknown
- 2016-07-12 HU HUE16738736A patent/HUE071541T2/hu unknown
- 2016-07-12 EP EP16738736.4A patent/EP3322722B1/en active Active
- 2016-07-12 RS RS20250497A patent/RS66840B1/sr unknown
- 2016-07-12 LT LTEPPCT/EP2016/066476T patent/LT3322722T/lt unknown
- 2016-07-12 CR CR20230300A patent/CR20230300A/es unknown
- 2016-07-12 UA UAA201800664A patent/UA125501C2/uk unknown
- 2016-07-12 CN CN202511963248.2A patent/CN121824750A/zh active Pending
- 2016-07-12 ES ES16738736T patent/ES3028882T3/es active Active
- 2016-07-12 TN TNP/2018/000005A patent/TN2018000005A1/en unknown
- 2016-07-12 MA MA42439A patent/MA42439B1/fr unknown
- 2016-07-12 MY MYPI2017001926A patent/MY194944A/en unknown
- 2016-07-12 CR CR20180021A patent/CR20180021A/es unknown
- 2016-07-12 KR KR1020257011170A patent/KR20250051158A/ko active Pending
- 2016-07-12 TW TW105121902A patent/TWI729992B/zh active
- 2016-07-12 JP JP2018501163A patent/JP7012004B2/ja active Active
- 2016-07-12 MX MX2018000504A patent/MX2018000504A/es unknown
- 2016-07-12 HR HRP20250624TT patent/HRP20250624T1/hr unknown
- 2016-07-12 RU RU2017145653A patent/RU2765303C2/ru active
- 2016-07-12 PT PT167387364T patent/PT3322722T/pt unknown
- 2016-07-12 CN CN202210997939.4A patent/CN115925921A/zh active Pending
- 2016-07-12 EA EA201792616A patent/EA036499B1/ru not_active IP Right Cessation
- 2016-07-12 GE GEAP202014670A patent/GEAP202014670A/en unknown
- 2016-07-12 SI SI201631902T patent/SI3322722T1/sl unknown
- 2016-07-12 CN CN201680039417.6A patent/CN107709361B/zh active Active
- 2016-07-12 AU AU2016292896A patent/AU2016292896B2/en active Active
- 2016-07-12 EP EP25154059.7A patent/EP4582144A3/en active Pending
- 2016-07-12 DK DK16738736.4T patent/DK3322722T3/da active
- 2016-07-12 GE GEAP201614670A patent/GEP20207151B/en unknown
- 2016-07-12 PL PL16738736.4T patent/PL3322722T3/pl unknown
-
2017
- 2017-11-14 US US15/812,303 patent/US10358483B2/en active Active
- 2017-11-14 US US15/812,410 patent/US10358484B2/en active Active
- 2017-11-14 US US15/812,363 patent/US10364285B2/en active Active
- 2017-11-14 US US15/812,251 patent/US10358482B2/en active Active
- 2017-12-15 CO CONC2017/0012941A patent/CO2017012941A2/es unknown
- 2017-12-18 ZA ZA2017/08607A patent/ZA201708607B/en unknown
- 2017-12-22 IL IL256501A patent/IL256501B/en unknown
-
2018
- 2018-01-03 PH PH12018500016A patent/PH12018500016A1/en unknown
- 2018-01-09 CL CL2018000075A patent/CL2018000075A1/es unknown
- 2018-01-11 DO DO2018000013A patent/DOP2018000013A/es unknown
- 2018-01-11 SV SV2018005612A patent/SV2018005612A/es unknown
- 2018-01-11 NI NI201800006A patent/NI201800006A/es unknown
- 2018-01-12 EC ECIEPI20182645A patent/ECSP18002645A/es unknown
- 2018-01-12 MX MX2023009483A patent/MX2023009483A/es unknown
-
2019
- 2019-06-17 US US16/443,225 patent/US10647764B2/en active Active
- 2019-06-17 US US16/443,187 patent/US10647763B2/en active Active
- 2019-06-17 US US16/443,249 patent/US10640554B2/en active Active
-
2020
- 2020-06-08 US US16/895,471 patent/US11524995B2/en active Active
- 2020-08-27 US US17/004,447 patent/US11421024B2/en active Active
- 2020-11-03 US US17/088,307 patent/US11542323B2/en active Active
-
2021
- 2021-08-24 JP JP2021136539A patent/JP7138322B2/ja active Active
-
2022
- 2022-08-29 JP JP2022136108A patent/JP7608404B2/ja active Active
- 2022-11-22 US US17/992,403 patent/US20230312693A1/en active Pending
-
2024
- 2024-12-18 JP JP2024221962A patent/JP2025041734A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47313B1 (fr) | Formulations sous-cutanées d'anticorps her2 | |
| TN2019000099A1 (en) | Anti-lag-3 antibodies and compositions | |
| PH12018500016A1 (en) | Agents, uses and methods for the treatment of synucleinopathy | |
| CL2021002503A1 (es) | Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251) | |
| MA41013A (fr) | Compositions comprenant des souches bactériennes | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| MA41596B1 (fr) | Anticorps anti-tau et leurs utilisations | |
| MA40290A1 (fr) | Agents immunorégulateurs | |
| MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
| JOP20200041A1 (ar) | تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي | |
| MA41758A (fr) | Procédés de traitement de l'infertilité | |
| MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| MX392158B (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MA46548A (fr) | Fsh pour le traitement de l'infertilité | |
| EP3628008A4 (en) | COMPOSITION AND METHOD OF TREATMENT OF ALZHEIMER'S MORBUS | |
| FR3060376B1 (fr) | Agent et procede pour la mise en forme temporaire de fibres keratiniques | |
| MA55752A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de néphropathies | |
| FR3070263B1 (fr) | Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite | |
| EP4537846A3 (en) | Anavex2-73 for the treatment of alzheimer s disease | |
| MA55888B1 (fr) | Hétéroarylaminopyrimidine amides inhibiteurs d'autophagie et leurs procédés d'utilisation |